Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
BrainsWay Ltd. logo

NASDAQ · BWAY

BrainsWay Ltd.

Healthcare · Medical - Devices

$11.36

Down-$0.57 (-4.78%)

Updated Oct 31, 2026, 8:35 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
345.63M
P/E ratio
66.66
Dividend yield
0.00%
52-week range
$7.14 – $17.40
Volume
123.87K
Avg. volume
67.63K

Price performance · BWAY

BWAY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

BWAY closed at $11.36 after 21 trading sessions, down 9.12% for the selected period.

Last close
$11.36
Period change
-9.12%
Period low
$11.21
Period high
$12.50
Daily close
View OHLC price history
BWAY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$11.58$11.58$11.16$11.36123.87K
Oct 29, 2026$11.85$12.05$11.5459$11.93121.73K
Oct 28, 2026$11.63$11.63$11.02$11.3789.44K
Oct 27, 2026$11.18$11.64$11.18$11.6374.16K
Oct 26, 2026$11.25$11.355$11.00$11.2175.06K
Oct 23, 2026$11.40$11.40$11.09$11.2552.46K
Oct 22, 2026$11.79$11.79$11.3612$11.4469.83K
Oct 21, 2026$12.00$12.07$11.8601$11.9841.21K
Oct 20, 2026$11.84$12.1903$11.735$12.0374.4K
Oct 19, 2026$11.86$12.15$11.837$11.99108.97K
Oct 16, 2026$11.87$11.87$11.365$11.4466.29K
Oct 15, 2026$11.51$11.905$11.34$11.82109.59K
Oct 14, 2026$11.70$11.79$11.47$11.51114.77K
Oct 13, 2026$11.86$12.18$11.80$11.92150.79K
Oct 12, 2026$11.56$11.63$11.41$11.46158.29K
Oct 9, 2026$11.36$12.13$11.36$11.77104.05K
Oct 8, 2026$11.59$11.6099$11.37$11.47119.71K
Oct 7, 2026$11.60$11.77$11.45$11.62132.36K
Oct 6, 2026$12.23$12.30$11.74$11.89143.63K
Oct 5, 2026$12.29$12.34$11.93$12.23231.2K
Oct 2, 2026$12.75$12.96$12.41$12.5050.83K

Latest BWAY news

The latest Smart Investors Daily articles mentioning BWAY.

Stock researchCompany · Overview

BWAY research

Overview

Company profile and research snapshot.

Company profile

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$24.00
Implied upside
—
Analysts
—
BWAY recent ratings
DateFirmRatingTarget
Aug 13, 2020Raymond JamesOutperform—
Mar 24, 2020Raymond JamesOutperform—
Mar 24, 2020Cantor FitzgeraldOverweight—
Nov 26, 2019Raymond JamesOutperform—
May 13, 2019OppenheimerOutperform—
Open full forecast

News briefing

Generated Oct 30, 2026, 9:12 PM

Why Is BWAY Down Today?

BrainsWay Ltd. shares declined 4.78% today, falling $0.57 in what appears to be a broader market pullback rather than company-specific negative news. The decline comes as the neurotech company prepares to report its third quarter 2026 financial results on November 10, 2026, with investors potentially taking profits ahead of the earnings announcement.

    Bottom line: BrainsWay's 4.78% decline appears driven by pre-earnings profit-taking rather than fundamentally negative developments, with the company poised to report Q3 2026 results on November 10. Investors should use this pullback to evaluate the company's commercial progress and clinical pipeline before the earnings announcement, as the stock's direction will likely hinge on whether management can demonstrate accelerating adoption of its neurotech solutions.

    Yahoo · Oct 28, 2026

    BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026

    BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2026 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 10, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time

    Yahoo · Oct 26, 2026

    BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives

    BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing coverage for the use of BrainsWay Deep TMS™ in the treatment of patients suffering from obsessive compulsive disorder (OCD). With this latest expansion, more than 118 million Americans are now cover

    Yahoo · Oct 19, 2026

    BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

    Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry TreatmentsBURLINGTON, Mass. and JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced a strategic collaboration with Inland Psychiatric Medical Group (“IPMG”), an established prov

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By